Paggiarino Dario A. 4

4 · EyePoint Pharmaceuticals, Inc. · Filed Apr 2, 2024

Form 4

Period: 2024-03-30

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2024-03-30+5,834→ 48,056 total
Exercise/Conversion
Restricted Stock Units
2024-03-30−30,570→ 0 total
Exercise: $0.00→ Common Stock (30,570 underlying)
Exercise/Conversion
Restricted Stock Units
2024-03-30−14,000→ 0 total
Exercise: $0.00→ Common Stock (14,000 underlying)
Exercise/Conversion
Restricted Stock Units
2024-03-30−5,834→ 0 total
Exercise: $0.00→ Common Stock (5,834 underlying)
Exercise/Conversion
Common Stock
2024-03-30+30,570→ 78,626 total
Exercise/Conversion
Common Stock
2024-03-30+14,000→ 92,626 total
Tax Payment
Common Stock
2024-03-30$20.67/sh−15,493$320,240→ 77,133 total
Tax Payment
Common Stock
2024-03-30$20.67/sh−2,957$61,121→ 74,176 total
Tax Payment
Common Stock
2024-03-30$20.67/sh−7,096$146,674→ 67,080 total

Footnotes (4)

[F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
[F2]The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
[F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
[F4]The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

Documents

1 file